BioMarin Pharmaceutical Inc. filed an amendment to its previous 8-K to provide required financial statements and pro forma financial information regarding its acquisition of Amicus Therapeutics, Inc. The filing includes audited financial statements for Amicus for the years 2023 through 2025 and unaudited pro forma condensed combined financial information as of December 31, 2025. BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes therapies for rare genetic diseases.